Skip to main content
. Author manuscript; available in PMC: 2018 Sep 1.
Published in final edited form as: Leukemia. 2018 Feb 23;32(6):1370–1379. doi: 10.1038/s41375-018-0039-7

Table 2.

Morphology and minimal residual disease assessments of end of Induction bone marrows, N(%)

MRD - B-ALL MRD – T-ALL
<5% 5–<25% ≥25% Total <5% 5–<25% ≥25% Total
Morphology M1 7 682 (97.8) 59 (0.8) 7 (0.1) 7 748 (98.6) 1 303 (87.3) 88 (5.9) 9 (0.6) 1 400 (93.8)
M2 28 (0.4) 29 (0.4) 11 (0.1) 68 (0.9) 10 (0.7) 25 (1.7) 15 (1.0) 50 (3.3)
M3 2 (0.0) 5 (0.1) 34 (0.4) 41 (0.5) 0 (0.0) 5 (0.3) 38 (2.5) 43 (2.9)
Total 7 712 (98.2) 93 (1.2) 52 (0.7) 7 857 (100) 1 313 (87.9) 118 (7.9) 62 (4.2) 1 493 (100)

ALL – acute lymphoblastic leukemia; MRD – minimal residual disease